COMPANY STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 MARCH 2018 ShareCapital based Share redemption Share Retained payment Treasury capital reserve premium earnings reserve shares Total m m m m m m m At 1 April 2016 74 6 690 4 899 1 2 5 668 Profit for the year 317 317 Dividends paid in theyear 62 62 At 31 March 2017 74 6 690 5 154 1 2 5 923 Loss for the year 1 120 1 120 Dividends paid in the year 58 58 Addition to share-based payment reserve 1 1 Settlement of share-based payment reserve 1 1 At 31 March 2018 74 6 690 3 976 1 1 4 746 The notes on pages 256 to 260 form an integral part of these financial statements.
254 MEDICLINIC | ANNUAL REPORT 2018 STRATEGIC REPORT GOVERNANCE AND REMUNERATION FINANCIAL STATEMENTS ADDITIONAL INFORMATION COMPANY FINANCIAL STATEMENTS COMPANY STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 MARCH 2018 2018 2017 Notes m m Operating activities Loss profit before tax 1 120 317 Adjustments for: Finance costs 6 Other income 6 33 27 Impairment of investments 3 1 169 Settlement of share-based payments 1 Dividend income 24 303 Net cash used in operating activities before movements in working capital 7 7 Change in balances with related parties 47 Change in other payables 2 Change in derivatives 1 Net cash used in generated from operating activities 7 37 Investing activities Dividend received 4 24 303 Net cash generated from investing activities 24 303 Financing activities Repayment of bank loan 265 Interest paid 6 Dividend paid 6 25 35 Net cash used in financing activities 25 306 Net movement in cash and cash equivalents 8 34 Cash and cash equivalents at the beginning of the year 34 Cash and cash equivalents at the end of the year 26 34 The notes on pages 256 to 260 form an integral part of these financial statements.
MEDICLINIC | ANNUAL REPORT 2018 255 NOTES TO THE COMPANY FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2018 1.
STATUS AND ACTIVITY Mediclinic International plc the Company or Parent is a Company which was incorporated in England and Wales on 20 December 2012.
The address of the registered office of the Company is C O Link Company Matters Limited, 6th Floor, 65 Gresham Street, London, EC2V 7NQ.
The registration number of the Company is 08338604.
There is no ultimate controlling party.
The domicile of the Company is the United Kingdom.
The Company is a public liability company with three operating divisions in Switzerland, Southern Africa South Africa and Namibia and the United Arab Emirates.
The activities of the subsidiaries are the operation of medical hospitals and clinics and the sale of pharmaceuticals, medical supplies and related equipment.
These financial statements are the separate financial statements of the Parent Company only and the financial statements of the Group are prepared and presented separately.
The financial statements are available at the registered office of the Company.
BASIS OF PREPARATION The Companys principal accounting policies applied in the preparation of these financial statements are the same as those set out in note 2 of the Groups financial statements, except as noted below.
These policies have been consistently applied to all the years presented.
Investments in subsidiaries are carried at cost less any accumulated impairment.
Dividend income is recognised when the right to receive payment is established.
The Company is taking advantage of the exemption in section 408 of the UK Companies Act not to present its individual income statement as part of these financial statements.
a Basis of measurement The financial statements of the Company are prepared in accordance with International Financial Reporting Standards IFRS, as adopted by the European Union, including IFRS Interpretations Committee IFRS IC applicable to companies reporting under IFRS.
The financial statements are prepared on the historical cost convention, as modified by the revaluation of certain financial instruments to fair value.
b Functional and presentation currency The financial statements and financial information are presented in pounds sterling, rounded to the nearest million.
c Going concern The Companys financial statements were prepared on a going concern basis.
The Directors believe that the Company will continue to be in operation in the foreseeable future.
INVESTMENT IN SUBSIDIARIES This investment is stated at cost less impairment.
2018 2017 m m Shares at cost 5 916 5 916 Less: impairment charge 1 169 Closing balance 4 747 5 916 256 MEDICLINIC | ANNUAL REPORT 2018 STRATEGIC REPORT GOVERNANCE AND REMUNERATION FINANCIAL STATEMENTS ADDITIONAL INFORMATION COMPANY FINANCIAL STATEMENTS 3.
INVESTMENT IN SUBSIDIARIES continued The investments held by the Company are Al Noor Holdings Cayman Limited, ANMC Management Limited, Mediclinic CHF Finco Limited, Mediclinic Holdings Netherlands B. V. Mediclinic Middle East Holdings Limited and Mediclinic International RF Pty Ltd, each being wholly-owned subsidiaries.
At the financial year end, the investment in Mediclinic Holdings Netherlands B. V. was impaired due to the impairment of the carrying values of properties and intangible assets of its underlying investment, Hirslanden AG.
An impairment charge of 1 169m was recorded in the Companys records.
Refer to notes 6 and 7 of the consolidated financial statements for more detail relating to the impairment calculation.
Refer to the Annexure to the notes to the consolidated financial statements on page 243 for a complete listing of investments in subsidiaries, associates and joint ventures of the Group and details of the country of incorporation, place of business, principal activities and interest in capital.
RELATED PARTY BALANCES AND TRANSACTIONS Related-parties comprise the subsidiaries, the shareholders, key management personnel and those entities over which the parent, the directors or the Company can exercise significant influence or which can significantly influence the Company.
2018 2017 m m a Transactions with key management personnel Key management includes the directors executive and non-executive and members of the executive committee Salaries and other short-term benefits 1 1 b Amount due to a related party: Mediclinic Hospitals LLC 26 26 This amount included the transaction and operational expenses paid by Mediclinic Hospitals LLC on behalf of the Company.
This amount is payable on demand.
Information regarding the Groups subsidiaries and associates can be found in the Annexure to the consolidated financial statements on pages 243 to 247. c Dividends received from related parties: Mediclinic CHF Finco Limited 4 49 Mediclinic Holdings Netherlands B. V. 8 7 Mediclinic International RF Pty Ltd 78 Mediclinic Middle East Holdings Limited 12 169 24 303 MEDICLINIC | ANNUAL REPORT 2018 257 NOTES TO THE COMPANY FINANCIAL STATEMENTS CONTINUED 5.
SHARE CAPITAL AND RESERVES 2018 2017 m m Issued and fully paid 737 243 810 2017: 737 243 810 shares of 10 pence each 74 74 OTHER RESERVES Share-based payment Treasury reserve shares Total m m m As at 1 April 2016 Addition of share-based payment reserve 1 2 1 As at 31 March 2017 1 2 1 Addition to share-based payment reserve 1 Settlement of share-based payment reserve 1 1 As at 31 March 2018 1 1 6.
DIVIDENDS The Company declared interim dividends for the 2017 18 period and final dividends for the 2016 17 period amounting to 58m.
The Company paid 25m 2017: 35m of these dividends, the remainder of 33m 2017: 27m was paid by the Dividend Access Trust.
A wholly-owned subsidiary of the Company, Mediclinic International RF Pty Ltd, formed a Dividend Access Trust to comply with a South African Reserve Bank requirement that dividends from a South African source due to SouthAfrican shareholders on the South African share register must be paid locally to avoid an outflow of funds from South Africa.
The beneficiaries of the trust are the South African shareholders of the Company who hold their shares via the South African share register on the relevant record date in respect of each distribution paid through the Dividend Access Scheme.
The Dividend Access Trust does not participate in any profits.
When a dividend is declared by the Company, the Dividend Access Trust would receive a dividend from Mediclinic International RF Pty Ltd which in turn is paid over to the Companys transfer secretaries in South Africa, who arrange for the payment of the relevant amount to the South African shareholders the beneficiaries of the trust through the usual dividend payment procedures, as if they were dividends received from Mediclinic International plc.
To the extent that the dividends due to South African shareholders are not ultimately funded from Mediclinic International RF Pty Ltd, they receive those dividends as normal dividends from Mediclinic International plc.
The South African shareholders entitlement to receive dividends declared by Mediclinic International plc is reduced by any amounts they receive via the trust.
Details on the final proposed dividend has been disclosed in note 28.6 to the consolidated financial statements.
258 MEDICLINIC | ANNUAL REPORT 2018 STRATEGIC REPORT GOVERNANCE AND REMUNERATION FINANCIAL STATEMENTS ADDITIONAL INFORMATION COMPANY FINANCIAL STATEMENTS 7.
AUDITORS REMUNERATION The Company incurred an amount of 448 758 2017: 337 900 to its auditor in respect of the audit of the Company and Groups financial statements for the year ended 31 March 2018.
The fee includes an amount of 42 959 2017: nil in respect of prior years.
Fees payable to the Companys auditors for other services: 2018 2017 m m Tax advisory services 0.25 Audit-related and other services 0.12 0.10 0.12 0.35 Relates to services rendered across the Group.
SHARE-BASED PAYMENT RESERVE Forfeitable Share Plan The Mediclinic International RF Pty Ltd Forfeitable Share Plan FSP was approved by the Companys shareholders in July 2014 as a long-term incentive scheme for selected senior management executive directors and prescribed officers.
This share-based payment arrangement is accounted for as an equity-settled share-based payment transaction.
The FSP shares will vest after the vesting period has lapsed.
Under the FSP, conditional share awards are granted to selected employees of the Group.
The vesting of these shares is subject to continued employment and measured over a three-year period.
2018 2017 Number of Number of shares shares As at 1 April 2017 2017: 1 April 2016 239 290 239 290 Vested during the year 137 948 As at 31 March 101 342 239 290 A valuation has been determined and an expense recognised over a three-year period.
The fair value of the total shareholder return TSR performance condition has been determined by using the Monte Carlo simulation model and the fair value of the headline earnings per share performance condition, consensus forecasts have been used.
The following assumptions were used with the valuation of the scheme: risk-free rate of 7.49%, dividend yield of 1.0% and volatility of 20%.
Apart from the FSP, there are no other share option schemes in place.
Therefore, no Director exercised any rights in relation to share option schemes during the reporting period.
TAXATION At 31 March 2018, the Company had unutilised tax losses of approximately 40m 2017: 33m.
No deferred tax asset has been recognised in respect of these losses.
MEDICLINIC | ANNUAL REPORT 2018 259 NOTES TO THE COMPANY FINANCIAL STATEMENTS CONTINUED 10.
FINANCIAL INSTRUMENTS a Capital risk management The Company manages its capital to ensure it is able to continue as a going concern while maximising the return on equity.
The Company does not have a formalised optimal target capital structure or target ratios in connection with its capital risk management objective.
The Companys overall strategy remains unchanged from the prior year.
The Company is not subject to externally imposed capital requirements.
b Financial risk management objectives The Company is exposed to the following risks related to financial instruments: credit risk, liquidity risk and foreign currency risk.
The Company does not enter into or trade in financial instruments, investments in securities, including derivative financial instruments, for speculative purposes.
c Credit risk The carrying amount of financial assets represents the maximum credit exposure.
There is no material credit risk involved on the Companys financial statements.
The Company's cash equivalents are placed with quality financial institutions with a high credit rating.
d Liquidity risk Ultimate responsibility for liquidity risk management rests with the directors of the Company, who have built an appropriate liquidity risk management framework for managing the Companys short, medium and long-term funding and liquidity management requirements.
The Company manages liquidity risk by maintaining adequate reserves by continuously monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities.
Liquidity risk is the risk that the Company will be unable to meet its funding requirements.
The table below summarises the maturity profile of the Companys financial liabilities.
The contractual maturities of the financial liabilities have been determined on the basis of the remaining period at the end of reporting period to the contractual repayment date.
The maturity profile is monitored by management to ensure adequate liquidity is maintained.
The maturity profile of the liabilities at the end of reporting period based on existing contractual repayment arrangements was as follows: Carrying Contractual 1 year amount cash flows or less m m m 31 March 2018 Other payables 1 1 1 Related-party payables 26 26 26 27 27 27 31 March 2017 Other payables 1 1 1 Related-party payables 26 26 26 27 27 27 e Foreign currency risk The Company has an insignificant exposure regarding foreign currency, but a prudent approach towards foreign cover is followed if applicable.
260 MEDICLINIC | ANNUAL REPORT 2018 STRATEGIC REPORT GOVERNANCE AND REMUNERATION FINANCIAL STATEMENTS ADDITIONAL INFORMATION ADDITIONAL INFORMATION MEDICLINIC MEDICLINIC | ANNU | ANNUAL REPOR AL REPORT 20 T 2018 18 2 261 61 SHAREHOLDER INFORMATION SHARE CAPITAL AND SHAREHOLDERS Structure The Companys ordinary issued share capital as at 31 March 2018 was 737 243 810 ordinary shares of 0.10 each which have a primary listing on the LSE and secondary listings on the JSE in South Africa and the NSX in Namibia.
The ordinary share class represents 100% of the Companys total issued share capital.
Further information on the Companys issued share AR capital can be found in note 13 to the Consolidated Financial Statements on pages 207 and 208.
There are no known arrangements under which financial rights are held by a person other than the holder of the shares.
Shares acquired through the Companys share schemes and plans rank equally with the other shares in issue and have AR no special rights.
Further details on the Companys employee share scheme are included in the Directors Remuneration Report from page 130.
Distribution of ordinary shareholders as at 31 March 2018 % of Number of issued shareNumber share holders of shares capital LSE register registered 649 220885 142 29.96% JSE register beneficial comprising: 29 273 516358 668 70.04% certificated 1 072 398 368 0.05% dematerialised 28 201 515960 300 69.99% Total 29 922 737243810 100.00% Acquisition of own shares At the Companys annual general meeting on 20 July 2016, it was resolved that the Company was authorised to purchase the 10 subscriber shares of 10 pence per share in the capital of the Company from Astro II SPV at a price of 10 pence per share, which repurchase was concluded in April 2017.
The Company has no intention to complete a market purchase of its ordinary shares and will not seek this authority at the Companys annual general meeting on 25 July 2018.
Restrictions on the transfer of Company shares The South African Broad-Based Black Economic Empowerment Act, 53 of 2003, as amended, the B-BEE Act was enacted to establish a legislative framework for the promotion of broad-based black economic empowerment in South Africa and is intended to encourage transformation by including black people in the economy.
It covers aspects such as ownership, management control, skills development, enterprise and supplier development and social-economic development.
In 2005, Mediclinic International RF Pty Ltd previously Mediclinic International Limited Mediclinic SA implemented a black ownership initiative with MP1 Investment Holdings Pty Ltd previously Circle Capital Ventures Pty Ltd MP1 and Phodiso Holdings Limited Phodiso collectively, the Strategic Black Partners.
Following the combination of Mediclinic SA with Al Noor Hospitals Group plc in February 2016, the Company entered into arrangements with the Strategic Black Partners to formalise the basis on which the Strategic Black Partners hold their shares in the Company, which are materially the same as the arrangements in existence prior to the combination.
The arrangements that originally applied to the holdings of the Strategic Black Partners in relation to their shares in Mediclinic SA before completion of the combination continue to apply to their holdings of shares in the Company.
The restrictions are: in the case of the 24 582 960 shares held by Phodiso through its subsidiary, Mpilo Investment Holdings 2 RF Pty Ltd Mpilo 2, representing approximately 3.33% of the Companys issued share capital, disposals of such shares are restricted until 31 December 2018: and 262 MEDICLINIC | ANNUAL REPORT 2018 STRATEGIC REPORT GOVERNANCE AND REMUNERATION FINANCIAL STATEMENTS ADDITIONAL INFORMATION SHAREHOLDER INFORMATION in the case of the 10 958 206 shares held by MP1 through its subsidiary, Mpilo 1 Newco RF Pty Ltd Mpilo 1, representing approximately 1.49% of the Companys issued share capital, disposals of such shares are restricted until 31 December 2019.
The arrangements also contain pre-emptive rights in favour of the Company which provide that, if any of the shares in the Company held by Mpilo 1 or Mpilo 2 are to be offered for sale, the Company will be offered the opportunity to purchase such shares or to nominate another person to purchase such shares, in each case, at a discounted price of, in relation to the Mpilo 1 shares, approximately 5% to the then market value and, in relation to the Mpilo 2 shares, approximately 10%.
Any exercise of a right to purchase such shares by the Company itself would require the approval of its shareholders.
Restrictions on voting rights The Companys Articles of Association provide that, unless the directors determine otherwise, a shareholder shall not be entitled to vote, either personally or by proxy, at any general meeting of the Company, or to exercise any other right conferred by membership if: any call or other sum payable to the Company in respect of that share remains unpaid: or such shareholder, having been duly served with a notice to provide the Company with information under section 793 of the UK Companies Act 2006, has failed to do so within 14 days of such notice, for so long as the default continues.
Substantial shareholders As at year end, and if subsequently changed also as at 23 May 2018, being the last practicable date, the following shareholders notified the Company, in accordance with Disclosure Guidance and Transparency Rules, of their interest of 3% or more in the Companys issued share capital: Ordinary % voting Date shares rights notified Remgro Limited through wholly-owned subsidiaries 328 497 888 44.56% 17 02 2016 Public Investment Corporation SOC Limited: as at year end 59 447 726 8.06% 12 05 2017 as at 23 May 2018 58894 769 7.99% 06 04 2018 Genesis Asset Managers LLP 37989 258 5.15% 28 11 2017 Coronation Asset Management Pty Ltd: as at year end 36951 344 5.01% 26 10 2017 as at 23 May 2018 36248 868 4.92% 07 05 2018 Mpilo Investment Holdings 2 RF Pty Ltd 24 582 960 3.33% 13 05 2016 2018 annual general meeting The Companys annual general meeting AGM will take place at 15:00 British Summer Time on Wednesday, 25 July 2018 at The Lincoln Centre, 18 Lincoln's Inn Fields, London, WC2A 3ED, United Kingdom.
All ordinary shareholders have the opportunity to attend and vote, in person or by proxy.
The Notice of Annual General Meeting can be found on the Investor Relations section of the Companys website at www.
com, and is being posted in a separate booklet at the same time as this Annual Report.
The notice sets out the business of the meeting and provides explanatory notes on all resolutions.
Separate resolutions are proposed in respect of each substantive issue.
The AGM is the Companys principal forum for communication with private shareholders.
The Chairman of the Board and the chairmen of the Board committees, together with senior management, will be available to answer shareholders questions at the meeting and the directors encourage shareholders to participate at the event.
MEDICLINIC | ANNUAL REPORT 2018 263 SHAREHOLDER INFORMATION CONTINUED DIVIDENDS The Board proposes a final dividend of 4,70 pence per ordinary share for the year ended 31 March 2018 for approval by the Companys shareholders at the AGM to be held on Wednesday, 25 July 2018.
The salient dates for the dividend are as follows: Last date to trade cum dividend SA register Tuesday, 12 June 2018 First date of trading ex-dividend SA register Wednesday, 13 June 2018 First date of trading ex-dividend UK register Thursday, 14 June 2018 Record date for final dividend Friday, 15 June 2018 Shareholder approval at annual general meeting London Wednesday, 25 July 2018 Final dividend payment date Monday, 30 July 2018 AR The Companys dividend policy is dealt with in the Financial Review on page 32.
The tax treatment of the dividend for shareholders on the South African register are available on the Companys website.
AR Details of the dividend access trust established for South African resident shareholders are provided in note 13 of the Consolidated Financial Statements on page 208.
The dividends declared by the Company to its ordinary shareholders during the reporting period are summarised below: 2018 2017 Interim dividend 3.20 3.20 Final dividend 4.70 4.70 Total dividend 7.90 7.90 SHARE PRICE The latest share price information can be found on the Companys website at www.
com or through your broker.
264 MEDICLINIC | ANNUAL REPORT 2018 STRATEGIC REPORT GOVERNANCE AND REMUNERATION FINANCIAL STATEMENTS ADDITIONAL INFORMATION SHAREHOLDER INFORMATION SHAREHOLDER SERVICES AND CONTACTS Shareholder enquiries Enquiries relating to shareholdings, including notification of change of address, queries regarding the loss of a share certificate and dividend payments should be made to the Companys registrars: Shareholders on the Southern African register South African transfer secretary Namibian transfer secretary Computershare Investor Services Pty Ltd Transfer Secretaries Pty Ltd Rosebank Towers, 15 Biermann Avenue, 4 Robert Mugabe Avenue, Windhoek, Namibia Rosebank, 2196, South Africa Postal address: PO Box 2401, Windhoek, Namibia Postal address: PO Box 61051, Tel: 264 61 227 647 Marshalltown, 2107, South Africa Fax: 264 61 248 531 Tel: 27 11 370 5000 Fax: 27 11 688 7716 Shareholders on the UK register Computershare Investor Services plc The Pavilions, Bridgwater Road, Bristol, BS99 6ZZ, United Kingdom Tel: 44 370 703 6022 E-mail: WebCorres@computershare.
co. uk Lines are open during normal business hours from 08:30 to 17:30 GMT Monday to Friday and charged at the standard rate.
Shareholders can use Computershares website to check and maintain their records.
Details can be found at www.
Share Dealing Service Computershare offers a share dealing service which allows UK resident shareholders to buy and sell the Companys shares.
Shareholders can deal in their shares on the internet or by telephone.
Please contact Computershare for more details on this service.
ShareGift If a few shares are held, which low value makes them difficult to sell, you may make a donation to charity through ShareGift, an independent charity share donation scheme.
For further details please contact the Computershare or ShareGift at telephone number 44 20 7930 3737 or visit their website at www.
MEDICLINIC | ANNUAL REPORT 2018 265 COMPANY INFORMATION COMPANY NAME AND NUMBER INVESTOR RELATIONS CONTACT Mediclinic International plc Mr James Arnold incorporated and registered in England and Wales Head of Investor Relations Company number: 08338604 14 Curzon Street, London, W1J 5HN, United Kingdom Tel: 44 20 3786 8180 1 REGISTERED OFFICE E-mail: ir@mediclinic.
com Mediclinic International plc REGISTRAR TRANSFER SECRETARIES 6th Floor, 65 Gresham Street London, EC2V 7NQ, United Kingdom United Kingdom Tel: 44 20 7954 9600 Fax: 44 20 7954 9886 Computershare Investor Services plc Ethics Line: 27 12 543 5332 Toll-free 0800 005 316 The Pavilions, Bridgwater Road, Bristol, BS99 6ZZ South Africa only ethics@mediclinic.
com South Africa Computershare Investor Services Pty Ltd LISTING Rosebank Towers, 15 Biermann Avenue, Rosebank, 2196 PO Box 61051, Marshalltown, 2107 FTSE sector: Health Care Equipment & Services Tel: 27 11 370 5000 ISIN code: GB00B8HX8Z88 SEDOL number: B8HX8Z8 Namibia EPIC number: MDC Transfer Secretaries Pty Ltd LEI: 2138002S5BSBIZTD5I60 4 Robert Mugabe Avenue, Windhoek Primary listing: London Stock Exchange share code: MDC PO Box 2401, Windhoek Secondary listing: JSE Limited share code: MEI Tel: 264 61 227 647 Secondary listing: Namibian Stock Exchange share code: MEP CORPORATE ADVISORS DIRECTORS Auditors  LLP, London Dr Edwin Hertzog ne Chairman South African, Corporate Broker and Sponsors Danie Meintjes Chief Executive Officer South African, Joint corporate brokers United Kingdom : Jurgens Myburgh Chief Financial Officer South African, Morgan Stanley & Co International plc Dr Muhadditha Al Hashimi ind ne Emirati, and UBS Investment Bank Jannie Durand ne South African, Alan Grieve ind ne JSE sponsor South Africa : British, Dr Felicity Harvey ind ne British, Seamus Rand Merchant Bank Keating ind ne Irish, Prof Dr Robert Leu ind ne Swiss, a division of FirstRand Bank Limited Nandi Mandela ind ne South African, Trevor Petersen NSX sponsor Namibia : ind ne South African, Desmond Smith Senior Simonis Storm Securities Pty Ltd Independent Director South African, Pieter Uys alternate to Jannie Durand South African Legal Advisors UK legal advisors: Slaughter and May COMPANY SECRETARY SA legal advisors: Cliffe Dekker Hofmeyr Inc. Link Company Matters Limited previously named Remuneration Consultant Capita Company Secretarial Services Limited New Bridge Street Jayne Meacham Caroline Emmet Deloitte LLP has been appointed from the 6th Floor, 65 Gresham Street, London, EC2V 7NQ 2018 19 financial year United Kingdom Communication Agency Tel: 44 20 7954 9600 FTI Consulting E-mail: @linkgroup.
co. uk Tel: 44 20 3727 1000 E-mail: businessinquiries@fticonsulting.
com 266 MEDICLINIC | ANNUAL REPORT 2018 STRATEGIC REPORT GOVERNANCE AND REMUNERATION FINANCIAL STATEMENTS ADDITIONAL INFORMATION COMPANY INFORMATION GLOSSARY TERM MEANING annual general meeting or AGM the annual general meeting of the Company to be held on Wednesday, 25 July 2018, the notice of which have been distributed to shareholders by Friday, 22 June 2018 and a copy of which is available on the Companys website Annual Report this annual report and financial statements for the reporting period ended 31 March 2018 Al Noor the Al Noor Hospitals Group with operations mainly in Abu Dhabi, which forms part of the Groups operations in the United Arab Emirates Articles the Companys Articles of Association as adopted in General Meeting on 20 July 2016 Board or Board of Directors the board of directors of Mediclinic International plc Brexit the departure of the United Kingdom from the European Union, which is planned from the end of March 2019 CAGR % compounded annual growth rate cash conversion % cash generated from operations divided by adjusted EBITDA CCU critical care unit CDLI Carbon Disclosure Leadership Index CEO Chief Executive Officer CFO Chief Financial Officer Company Mediclinic International plc DRG diagnosis-related group EBITDA operating profit before depreciation and amortisation, excluding other gains and losses EU European Union external auditor when referring to the Companys external auditor, means  LLP FY18 period under review reporting the financial year ended on 31 March 2018 period FY19 next financial year the financial year ending on 31 March 2019 FCA the United Kingdom Financial Conduct Authority GDP gross domestic product GRI Standards the GRI Sustainability Reporting Standards issued in 2016 by the Global Sustainability Standards Board, which standards represent global best practice for reporting publicly on a range of economic, environmental and social impacts Group Mediclinic International and its three operating divisions in Switzerland, Southern Africa and the United Arab Emirates group refers to one of the Groups operating divisions, as the context may indicate, as defined below group one of the operating divisions of the Group, as the context may indicate please note that group is as defined in this definition and Group refers to the entire Mediclinic Group as defined above HAI  infection Hirslanden the Groups operations in Switzerland, trading under the Hirslanden brand, with Hirslanden AG as the intermediary holding company of the Groups operations in Switzerland IFRS International Financial Reporting Standards, as adopted by the European Union MEDICLINIC | ANNUAL REPORT 2018 267
